Here's Why Cara Therapeutics Jumped 56.5% in the First Half of 2018

Shares of Cara Therapeutics (NASDAQ:CARA), a clinical-stage biotech developing novel pain-management drugs, soared 56.5% during the first half of 2018, according to data from S&P Global Market Intelligence. Two big announcements drove the stock higher: an important new partnership with a leading dialysis service provider and a positive pivotal trial result for the company's lead candidate.